{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:45:54Z","timestamp":1793270754025,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K09606"],"award-info":[{"award-number":["15K09606"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10157-017-1525-3","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T05:15:45Z","timestamp":1514524545000},"page":"843-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy"],"prefix":"10.1007","volume":"22","author":[{"given":"Hitoshi","family":"Sakuraba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"1525_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"1525_CR2","first-page":"75","volume-title":"Fabry disease: perspective from 5 years of FOS","author":"TM Cox","year":"2006","unstructured":"Cox TM. Biomarkers in lysosomal storage disease. In: Mehta A, Beck M, Sunder Plassman G, editors. Fabry disease: perspective from 5 years of FOS. Oxford: Oxford PharmaGenesis. 2006;pp.\u00a075\u201391."},{"key":"1525_CR3","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1525_CR4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","volume":"1802","author":"SM Rombach","year":"2010","unstructured":"Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"1525_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","volume":"100","author":"T Togawa","year":"2010","unstructured":"Togawa T, Kodama T, Suzuki T, Sugawara K, Tsukimura T, Ohashi T, et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab. 2010;100:257 \u2013 61.","journal-title":"Mol Genet Metab"},{"key":"1525_CR6","doi-asserted-by":"publisher","first-page":"e0127048","DOI":"10.1371\/journal.pone.0127048","volume":"10","author":"H Sueoka","year":"2015","unstructured":"Sueoka H, Ichihara J, Tsukimura T, Togawa T, Sakuraba H. Nano-LC\u2013MS\/MS for quantification of lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease. PLoS One. 2015;10:e0127048.","journal-title":"PLoS One"},{"key":"1525_CR7","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibei T, et al. Enzyme replacement therapy in Fabry disease: a randamized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"1525_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"MJ van Breemen","year":"2011","unstructured":"van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812:70 \u2013 6.","journal-title":"Biochim Biophys Acta"},{"key":"1525_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256 \u2013 64.","journal-title":"J Am Soc Nephrol"},{"key":"1525_CR10","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JM, Poorthuis BJ, Groener JE, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One. 2012;7:e47805.","journal-title":"PLoS One"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","volume":"59","author":"H Gold","year":"2013","unstructured":"Gold H, Mirzaian M, Dekker N, Ferraz MJ, Lugtenburg J, Cod\u00e9e JDC, et al. Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. Clin Chem. 2013;59:547 \u2013 56.","journal-title":"Clin Chem"},{"key":"1525_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","volume":"26","author":"MD Sanchez-Ni\u00f1o","year":"2011","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol Dial Transplant. 2011;26:1797 \u2013 802.","journal-title":"Nephrol Dial Transplant"},{"key":"1525_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"PB Deegan","year":"2012","unstructured":"Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35:227 \u2013 43.","journal-title":"J Inherit Metab Dis"},{"key":"1525_CR14","doi-asserted-by":"publisher","first-page":"e0128351","DOI":"10.1371\/journal.pone.0128351","volume":"10","author":"S Nakano","year":"2015","unstructured":"Nakano S, Tsukimura T, Togawa T, Ohashi T, Kobayashi M, Takayama K, et al. Rapid immunochromatographic detection of serum anti-\u03b1-galactosidase A antibodies in Fabry patients after enzyme replacement therapy. PLoS One. 2015;10:e0128351.","journal-title":"PLoS One"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-017-1525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-017-1525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:39:54Z","timestamp":1589449194000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-017-1525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1007\/s10157-017-1525-3","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,29]]},"assertion":[{"value":"14 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by Sumitomo Dainippon Pharma Co., Ltd. (SDP) and the Japan Society for the Promotion of Science (ID: 15K09606, HS). These were used solely for research activity. Although H. Kato is an employee of SDP, he has no competing interest. We declare that none of the authors have any competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethical committees of Meiji Pharmaceutical University (IDs 2616 and 2617) and Sumitomo Dainippon Pharma Co., Ltd. (IDs 2015-02 and 2015-03), and was performed according to the ethical guidelines of the 1975 Declaration of Helsinki. The institutional review board or independent ethics committee at each hospital also approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"This study has been registered in UMIN (IDs 000016854 and 000017152).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration of clinical trials"}},{"value":"All participants and\/or their parents provided written informed consent or assent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}